QLI - Rasio utang marang kapitalisasi buku Qilian International Holding Group Limited

Tandha merek Qilian International (QLI)

Qilian International (QLI) generates revenue through the sale of veterinary antibiotics, licorice extracts, and pharmaceutical products. The current leverage ratio on the balance sheet from the GURU.Markets terminal is provided by a chart where 0.01 captures the current state of the parameter. Stability is ensured by delegating raw material procurement to farmers, while modern filtration and wastewater treatment systems guarantee the environmental sustainability of production.

qlsyy.net - Utang-utang marang kapitalisasi buku QLI (periode 04.07.2022 - 17.08.2024)
Barang unggulan Qilian International Corp

Environmental regulatory pressure in China and heparin price volatility are increasing operating costs for Qilian International (QLI). This metric measures the share of total liabilities within the equity structure, determining the financial stability of assets. A declining ratio indicates increasing solvency and the minimization of credit risks. It is critical for investors to track the dynamics of debt coverage by net equity. By analyzing the correlation between debt size and balance sheet equity, one can assess the actual protection of the business.

Pesaing Qilian International

Rasio utang marang kapitalisasi buku Haleon plc|kenvue.com - Rasio utang marang aset resik|VRNA: Rasio utang marang kapitalisasi buku|MENS - Utang marang nilai buku|LGND: Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Amneal Corp|PRGO - Utang marang nilai buku|Rasio utang marang aset resik ALVO|Liquidia - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Galapagos N.V. GLPG|Utang marang nilai buku ANI Pharma (ANIP)|Utang marang modal buku Afrezza MNKD|Utang-utang marang kapitalisasi buku Amphastar Pharmaceuticals (AMPH)|PCRX - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku SPRY|TBPH (Theravance Biopharma Inc) - Utang-utang marang nilai buku|AQST - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik SCPH|TECX: Rasio utang marang kapitalisasi buku|Utang marang aset resik tonixpharma.com (TNXP)|Utang-utang marang kapitalisasi buku SXTC|Eupraxia Pharmaceuticals, Inc. - Utang-utang marang aset resik|BHST - Rasio utang marang kapitalisasi buku|EXOZ - Rasio utang marang kapitalisasi buku|oramed.com - Utang-utang marang kapitalisasi buku|Entera Bio (ENTX) - Utang-utang marang aset resik|HYFT (MindWalk Holdings Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku ABVC|Rasio utang marang kapitalisasi buku Cumberland Pharma CPIX|Rasio utang marang nilai buku Quantum BioPharma Corp QNTM|Utang marang nilai buku FibroGen, Inc.|Rasio utang marang aset resik telomirpharma.com TELO|Utang-utang marang kapitalisasi buku RANI (Rani Therapeutics Inc)|SNYR: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku rallybio.com|Rasio utang marang nilai buku Lexaria Bioscience Corp.|Pulmatrix, Inc. (PULM) - Utang marang nilai buku|Utang marang modal buku Pheton|Aptorum Group Limited - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku LYRA (Lyra Therapeutics Inc.)|Rasio utang marang kapitalisasi buku Impact BioMedical Inc|TNF Pharmaceuticals Inc. - Rasio utang marang aset resik|cbdMD Corp (YCBD) - Rasio utang marang kapitalisasi buku|PRFX - Rasio utang marang nilai buku|CYTO: Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Lipella Pharmaceuticals Inc|Optinose (OPTN) - Utang marang nilai buku|Utang marang modal buku Pieris Pharma|PROC (Procaps Group S.A.) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik PTPI (petrospharma.com)|SLRN: Rasio utang marang kapitalisasi buku|TFF Pharmaceuticals Inc. - Utang-utang marang nilai buku